Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data ...
More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...
Maldives achieves historic milestone in eliminating mother-to-child transmission of HIV, syphilis, and Hepatitis B, setting ...
Young women are contracting HIV faster than anyone else in South Africa, with about four out of every 10 new infections coming from just this group, even though they make up only about 8% of the total ...